Jochen Knolle
Fondateur chez Pharvaris GmbH
Fortune : 28 M $ au 31/05/2024
Profil
Jochen Knolle is the founder of JCK Consult Ltd.
(2008), Pharvaris NV (2015), and Pharvaris GmbH (2015) where he held the title of Chief Operating & Scientific Officer.
He is also the founder of 3B Pharmaceuticals GmbH and Kosa Pharma GmbH.
Dr. Knolle's current jobs include Director positions at Anchor Therapeutics, Inc., Thermosome GmbH, Charité Research Organisation GmbH, and Venture Partner at TVM Capital GmbH.
Dr. Knolle's former jobs include Vice President-Medicinal Chemistry at Axys Pharmaceuticals, Inc. and Chief Scientific Officer at Shire Orphan Therapies GmbH (2001-2008).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PHARVARIS N.V.
2,70% | 01/04/2024 | 1 450 617 ( 2,70% ) | 28 M $ | 31/05/2024 |
Postes actifs de Jochen Knolle
| Sociétés | Poste | Début |
|---|---|---|
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Analyste en capital-investissement | - |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Thermosome GmbH
 Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | Directeur/Membre du Conseil | - |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Fondateur | 01/10/2015 |
Charité Research Organisation GmbH
 Charité Research Organisation GmbH Miscellaneous Commercial ServicesCommercial Services Charité Research Organisation GmbH is a contract research organization that helps clients move development projects from first time in human to proof of concept as quickly and efficiently as possible. The private company is based in Berlin, Germany and was founded in 2005 by Frank Wagner, who has been the CEO since then. Charité Research Organisation offers scientific and regulatory consultancy, protocol development, routine laboratory, biomarker laboratory, imaging, project management, monitoring, data management, biostatistics, and medical writing services. The German company also provides world-leading patient and healthy volunteer recruitment capabilities and delivers the best value solution for early clinical development. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jochen Knolle
| Sociétés | Poste | Fin |
|---|---|---|
| PHARVARIS N.V. | Fondateur | 05/01/2024 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Directeur Technique/Scientifique/R&D | 01/01/2008 |
| Kosa Pharma GmbH | Fondateur | - |
3B Pharmaceuticals GmbH
 3B Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services 3B Pharmaceuticals GmbH is a German biotechnology company that specializes in developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. The company is based in Germany. The private company is a leader in peptide discovery and optimization, with a technology platform that extends from hit identification to early clinical development. The company is owned by its founders and management. 3BP was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Bern and Basel. The company was founded in 2008 by Jochen Knolle. The CEO is Ulrich Reineke. | Fondateur | - |
| ░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHARVARIS N.V. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Axys Pharmaceuticals, Inc.
 Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Thermosome GmbH
Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | Health Technology |
Charité Research Organisation GmbH
Charité Research Organisation GmbH Miscellaneous Commercial ServicesCommercial Services Charité Research Organisation GmbH is a contract research organization that helps clients move development projects from first time in human to proof of concept as quickly and efficiently as possible. The private company is based in Berlin, Germany and was founded in 2005 by Frank Wagner, who has been the CEO since then. Charité Research Organisation offers scientific and regulatory consultancy, protocol development, routine laboratory, biomarker laboratory, imaging, project management, monitoring, data management, biostatistics, and medical writing services. The German company also provides world-leading patient and healthy volunteer recruitment capabilities and delivers the best value solution for early clinical development. | Commercial Services |
3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services 3B Pharmaceuticals GmbH is a German biotechnology company that specializes in developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. The company is based in Germany. The private company is a leader in peptide discovery and optimization, with a technology platform that extends from hit identification to early clinical development. The company is owned by its founders and management. 3BP was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Bern and Basel. The company was founded in 2008 by Jochen Knolle. The CEO is Ulrich Reineke. | Commercial Services |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Health Technology |
| JCK Consult Ltd. | |
| Kosa Pharma GmbH |
